NewAmsterdam Pharma Appoints Principal Accounting Officer

What Happened
NewAmsterdam Pharma Company N.V. filed an 8-K on August 14, 2026 announcing that Robert W. Gunning (age 55) was appointed principal accounting officer effective August 10, 2026. Mr. Gunning joined the company as Vice President, Controller on August 10, 2026 and succeeds Louise Kooij, whose departure effective August 31, 2026 was previously announced.

Key Details

• Base salary: $375,000 per year (Offer Letter dated July 24, 2026).
• Annual bonus: eligible for cash bonus with a target of 30% of base salary, prorated for 2026 and subject to board discretion.
• Equity: restricted stock unit award of 3,200 ordinary shares and a stock option to purchase 14,000 ordinary shares to be granted under the Company’s 2024 Inducement Plan.
• Background: prior roles include VP Finance & Corporate Controller at Y-mAbs (Apr 2022–Apr 2026) and interim controller/consultant at Altimmune (Apr–Jul 2026); holds a BBA from Pace University.
• Governance notes: no family relationships or related-party transactions requiring disclosure; standard indemnification agreements apply. The company intends to file a copy of the Offer Letter with its Form 10-Q for the quarter ending September 30, 2026.

Why It Matters
This is a leadership change in the company’s finance function: the principal accounting officer plays a key role in financial reporting and controls. Investors should note the appointment and the compensation/equity terms, but the filing does not disclose any restatements or changes to financial results. The company previously announced the predecessor’s departure, and the new officer’s hire supports continuity ahead of upcoming periodic filings.